Sarcopenia is linked to elevated levels of proinflammatory cytokines, the company said. The study aimed to enroll 40 participants aged 65 years and older with chronic inflammation associated with sarcopenia—a term for the age-related progressive loss of muscle mass and strength. Over 28 days, they received weekly doses of either 600 mg, 750 mg, 900 mg or 1050 mg of the TNF-α inhibitorTNF-α inhibitor, dubbed MYMD-1, or placebo. In a Monday morning release, the company reported that the drug hit both of the trial’s primary endpoints: significantly reducing serum levels of the biomarkers TNF-α, sTNFR1 and IL-6; as well as maintaining appropriate plasma concentrations and parameters in pharmacokinetic evaluations. The study also hit all of its secondary endpoints, which related to safety and tolerability with no treatment-related adverse events reported. Investors seemed pleased with the results, sending the company’s stock up 22% to $1.34 per share in the opening hour of trading Monday from a Friday close of $1.09.
Sarcopenia is linked to elevated levels of proinflammatory cytokines, the company noted in the release, hence the focus on biomarkers like TNF-α, a pro-inflammatory agent.